BridgeBio Pharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BridgeBio Pharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-75.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 78% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$57Sales grew 547% in 3 years, but profit fell: $57 less profit per $100 of extra sales.
Lower than 84% of Healthcare companies in United States.
Asset Productivity Ratio
+547% / +50%In 3 years sales changed by +547% while total assets changed by +50%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-72.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 78% of Healthcare companies in United States.
Cash Cushion Ratio
−10%Debt, after subtracting cash, equals 10% of its market value (net debt).
Lower than 78% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 80% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
BridgeBio Pharma, Inc. made a loss over the last year. BridgeBio Pharma, Inc. owes $3.06 for every $1 it owns. BridgeBio Pharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBridgeBio Pharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-5.29BridgeBio Pharma, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$13.3 BThe total market value of all of BridgeBio Pharma, Inc.'s shares at today's price (share price × number of shares), larger than 92% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
NegativeBridgeBio Pharma, Inc.'s net worth is negative ($2.5 B below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
3.06×BridgeBio Pharma, Inc. owes $3.06 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Dividend yield
NoneBridgeBio Pharma, Inc. does not currently pay a dividend.
Revenue growth
+126%Revenue rose 126% in the year to Dec 2025, and grew 86% a year on average over 3 years.
Profit growth
LossBridgeBio Pharma, Inc. made a loss in each of the last two years.
Profit margin
-144.4%BridgeBio Pharma, Inc. lost $144 for every $100 of revenue.
Interest cover
Not coveredBridgeBio Pharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtBridgeBio Pharma, Inc. had $1.3 B more debt than cash (net debt) at Dec 2025.
Questions
How much does BridgeBio Pharma, Inc. owe compared with what it owns?
BridgeBio Pharma, Inc. owes $3.06 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Does BridgeBio Pharma, Inc. pay a dividend?
No. BridgeBio Pharma, Inc. does not currently pay a dividend.
Is BridgeBio Pharma, Inc.'s revenue growing?
Revenue rose 126% in the year to Dec 2025, and grew 86% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.